76568-68-8

Basic information

• Product Name: flosequinoxan
• Synonyms: flosequinoxan;7-Fluoro-1-methyl-3-(methylsulfonyl)-4(1H)-quinolinone;7-Fluoro-1-methyl-3-(methylsulfonyl)quinolin-4(1H)-one;7-Fluoro-1-methyl-3-methylsulfonylquinolin-4(1H)-one;BTS-53554;Flosequinan sulphone
• CAS NO: 76568-68-8
• Molecular Formula: C11H10 F N O3 S
• Molecular Weight: 0
• Mol File: 76568-68-8.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 440.2°C at 760 mmHg
• Flash Point: 220°C
• Appearance: /
• Density: 1.46g/cm³
• Vapor Pressure: 6E-08mmHg at 25°C
• Refractive Index: 1.61
• CAS DataBase Reference: flosequinoxan(CAS DataBase Reference)
• NIST Chemistry Reference: flosequinoxan(76568-68-8)
• EPA Substance Registry System: flosequinoxan(76568-68-8)

Safety Data

• Hazardous Substances Data: 76568-68-8(Hazardous Substances Data)

Usage

InChI:InChI=1/C11H10FNO3S/c1-13-6-10(17(2,15)16)11(14)8-4-3-7(12)5-9(8)13/h3-6H,1-2H3

Upstream product

• 372-19-0 meta-fluoroaniline 
• 154504-93-5 (+)-Flosequinan 
• 154504-94-6 (-)-Flosequinan 
• 154639-78-8 7-fluoro-3-methylsulfonyl-4-quinolone 
• 74-88-4 methyl iodide 
• 76568-02-0 flosequinan 
• 128992-62-1 4-fluoro-N-methylanthranilic acid 
• 154639-75-5 1-(4-fluoro-2-methylaminophenyl)-2-methylsulfinylethanone 
• 76561-14-3 7-fluoro-3-methylsulfinyl-4-quinolone 
• 76561-13-2 1-(2-amino-4-fluorophenyl)-2-methylsulfinylethanone 
• 97927-92-9 7-fluoro-1-methyl-2H-benzo[d][1,3]oxazine-2,4(1H)-dione 
• 2252-51-9 2-choro-4-fluorobenzoic acid 
• 321-50-6 7-fluoro-1H-benzo[d][1,3]oxazine-2,4-dione 

Relevant articles and documents

Stereoselective S-oxidation and reduction of flosequinan in rat

1. The stereoselective S-oxidation and reduction pathways of flosequinan [(±)-7-fluoro-1-methyl-3-methylsulphinyl-4-quinolone] in rat were investigated in vitro. 2. Cytosol from both the liver and kidney catalysed the reduction of R(+)-flosequinan (R-FSO) and S(-)-flosequinan (S-FSO) to flosequinan sulphide (FS, 7-fluoro-1-methyl-3-methylthio-4-quinolone). Flosequinan sulphone (FSO22, 7-fluoro-1-methyl-3-methyl-sulphonyl-4-quinolone) was not reduced to R-FSO or S-FSO. 3. Liver microsomes catalysed four different S-oxidation pathways in the presence of NADPH, namely oxidation of FS to R-FSO and S-FSO and from R-FSO and S-FSO to FSO2. The formation of R-FSO and S-FSO from FS each eshibited a biphasic kinetic pattern, indicating that at least two distinct enzymes were involved. The pathway from FS to R-FSO appeared mainly catalysed by flavin-containing monooxygenases (FMO). 4. S-oxidation of FS to R-FSO was more rapid than that of FS to S-FSO. S-oxidation of FS to either R-FSO or S-FSO in liver microsomes was more rapid than that of either R-FSO or S-FSO to FSO2. 5. Microsomes from both the kidney and lung catalysed the stereoselective S-oxidation of FS to R-FSO, and FMO was likely to have participated in these reactions.

Process for the preparation of 1-methyl-3-methylthio-4-quinolone and the sulfinyl, and sulfonyl analogs thereof

A process to prepare compounds of formula I STR1 in which n=0, 1 or 2 comprising the cyclisation of compounds of formula II STR2 in which n=0, 1 or 2. The cyclisation may be effected in the presence of an organic or inorganic base or thermally at a temper

Method of treating heart disease

A method for the treatment of heart failure in a mammal comprises the administration to the mammal of a quinolone of the general formula I, STR1 wherein m is 0 or 1; n is 0, 1 or 2; and R is hydrogen, halo, methyl or trifluoromethyl. A preferred method of the invention comprises the treatment of chronic heart failure in a mammal by the oral administration of a quinolone of formula I. Preferred compounds of formula I are 7-fluoro-1-methyl-3-methylsulphinyl-4-quinolone and 1-methyl-3-methylsulphonylmethyl-4-quinolone.